ASB10

Across TCGA pan-cancer cohorts, ASB10 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ASB10 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ASB10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ASB10 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

ACC, HNSC, and BRCA are the cancer types where ASB10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.145	0.888	<.001	45	view →
HNSC	DFS	Median	III,IV	0.087	0.680	<.001	20	view →
BRCA	OS	Median	All	0.112	0.578	.016	18	view →
GBM	DFS	Median	All	1.000	0.191	.022	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LGG	OS	Median	All	0.415	0.811	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ASB10–ACC (OS)

Open the ACC breakdown →